Exelixis Inc. (EXEL)
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket
When Wall Street's growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles.
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Exelixis: Financial Performance Improves Faster Than Market Expectations
Exelixis remains undervalued despite a 13%+ rally post-Q1, supported by robust double-digit growth, sector-leading profitability, and strong free cash flow. Q1 revenue grew 10% year-over-year, driven almost entirely by CABOMETYX demand; operating margin expanded to 41.1% as costs fell. I maintain a Buy rating with a $57 target, reflecting 13% upside; DCF and peer multiples confirm the valuation gap persists.
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
Exelixis NASDAQ: EXEL remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company's senior vice president of strategy, said during a session hosted by RBC Capital Markets.
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
Here's Why Exelixis (EXEL) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
